FGFR1 and lung carcinoma: To identify the genetic determinants underlying sensitivity to FGFR-targeted therapy, Z. Yang et al. performed a CRISPR/Cas9 kinome (human protein kinases) knockout in FGFR1-enhanced lung cancer cells [50].